Merck (MRK) Tops Q4 EPS by 1c, Offers FY Guidance

February 5, 2020 6:49 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Merck (NYSE: MRK) reported Q4 EPS of $1.16, $0.01 better than the analyst estimate of $1.15. Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.98 billion.

GUIDANCE:

Merck sees FY2020 EPS of $5.62-$5.77, versus the consensus of $5.61. Merck sees FY2020 revenue of $48.8-50.3 billion, versus the consensus of $49.53 billion.

  • At mid-January 2020 exchange rates, Merck anticipates full-year 2020 revenue to be between $48.8 billion and $50.3 billion, including a negative impact from foreign exchange of less than 1%.
  • Merck expects full-year 2020 GAAP EPS to be between $4.57 and $4.72. Merck expects full-year 2020 non-GAAP EPS to be between $5.62 and $5.77, including an approximately 1.5% negative impact from foreign exchange. The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs.

For earnings history and earnings-related data on Merck (MRK) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities

Earnings, Definitive Agreement